Ionela Daniela Popescu

Ionela Daniela Popescu

Auto-generated profile, based on publicly available information

Ionela Daniela Popescu

Victor Babes National Institute of Pathology, 050096 Bucharest, Romania

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SMSimona Mihai
Simona Mihai
ECElena Codrici
Elena Codrici
IPIonela Daniela Popescu
Ionela Daniela Popescu
AEAna-Maria Enciu
Ana-Maria Enciu
LALucian Albulescu
Lucian Albulescu
CTCristiana Tanase
Cristiana Tanase
Persistent, low-grade inflammation is now considered a hallmark feature of chronic kidney disease (CKD), being involved in the development of all-cause mortality of these patients. Although substantial improvements have been made in clinical care, CKD remains a major public health burden, affecting 10–15% of the population, and its prevalence is constantly growing. Due to its insidious nature, CKD is rarely diagnosed in early stages, and once developed, its progression is unfortunately irreversible. There are many factors that contribute to the setting of the inflammatory status in CKD, including increased production of proinflammatory cytokines, oxidative stress and acidosis, chronic and recurrent infections, altered metabolism of adipose tissue, and last but not least, gut microbiota dysbiosis, an underestimated source of microinflammation. In this scenario, a huge step forward was made by the increasing progression of omics approaches, specially designed for identification of biomarkers useful for early diagnostic and follow-up. Recent omics advances could provide novel insights in deciphering the disease pathophysiology; thus, identification of circulating biomarker panels using state-of-the-art proteomic technologies could improve CKD early diagnosis, monitoring, and prognostics. This review aims to summarize the recent knowledge regarding the relationship between inflammation and CKD, highlighting the current proteomic approaches, as well as the inflammasomes and gut microbiota dysbiosis involvement in the setting of CKD, culminating with the troubling bidirectional connection between CKD and renal malignancy, raised on the background of an inflammatory condition.

4 July 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AEAna-Maria Enciu
Ana-Maria Enciu
EREugen Radu
Eugen Radu
IPIonela Daniela Popescu
Ionela Daniela Popescu
MHMihail Eugen Hinescu
Mihail Eugen Hinescu
LCLaura Cristina Ceafalan
Laura Cristina Ceafalan
Metastasis requires cellular changes related to cell-to-cell and cell-to-matrix adhesion, immune surveillance, activation of growth and survival signalling pathways, and epigenetic modifications. In addition to tumour cells, tumour stroma is also modified in relationship to the primary tumour as well as to distant metastatic sites (forming a metastatic niche). A common denominator of most stromal partners in tumour progression is CD36, a scavenger receptor for fatty acid uptake that modulates cell-to-extracellular matrix attachment, stromal cell fate (for adipocytes, endothelial cells), TGFβactivation, and immune signalling. CD36 has been repeatedly proposed as a prognostic marker in various cancers, mostly of epithelial origin (breast, prostate, ovary, and colon) and also for hepatic carcinoma and gliomas. Data gathered in preclinical models of various cancers have shown that blocking CD36 might prove beneficial in stopping metastasis spread. However, targeting the receptor in clinical trials with thrombospondin mimetic peptides has proven ineffective, and monoclonal antibodies are not yet available for patient use. This review presents data to support CD36 as a potential prognostic biomarker in cancer, its current stage towards achievingbona fidebiomarker status, and knowledge gaps that must be filled before further advancement towards clinical practice.

2 September 2018 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
IIIoana Catalina Ionescu
Ioana Catalina Ionescu
CCCatalina Gabriela Corbu
Catalina Gabriela Corbu
CTCristiana Tanase
Cristiana Tanase
GIGabriela Ionita
Gabriela Ionita
CNCristina Nicula
Cristina Nicula
LVLiliana-Mary Voinea
Liliana-Mary Voinea
Keratoconus is a progressive corneal ectasia that may lead to severe visual impairment due to the irregular astigmatism caused by corneal thinning. In addition to its association with atopy, eye rubbing, or genetic component, late reports suggest the involvement of inflammation in the pathogenesis of the disease. Our aim was to determine the concentration of IL-4, IL-6, IL-10, RANTES, IFN gamma, and TNF alpha in the tear film of patients with keratoconus and their first degree family members. We analyzed forty-eight participants in an observational cross-sectional study. The diagnosis of keratoconus had to be confirmed in addition to a minimum of 47 D corneal refractive power by corneal topography readings provided by a Placido-based topography system and analysis of the pattern: irregular astigmatism with an asymmetric “bow-tie.” As for the other groups, the most important diagnosis criteria were a normal topographic pattern with a regular astigmatism. 17 keratoconus patients, 16 relatives, and 15 controls were recruited after clinical assessment as part of the research. The cytokine’s mean values were similar in the keratoconus group and the relatives’ samples but significantly higher compared to the controls. Important differences were found in IL-4 levels between keratoconus patients and relatives and between relatives and controls (mean difference of 302.42, p<0.0016 and 219.16, p<0.033, Tukey’s HSD procedure). In the keratoconus group, using the CORR procedure, we found statistically strong correlations of IL-6 lacrimal concentrations with the disease stage (r=0.56, p<0.01), keratometry (r=0.55, p<0.02), pachymetry (r=−0.64, p<0.048), and corneal hysteresis (r=−0.53, p<0.02). Cytokine overexpression may be relevant for the inflammatory etiology of keratoconus. In conclusion, in the case of some first degree family members, the elevated tear biomarkers may represent a supplementary risk factor.

29 August 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ECElena Codrici
Elena Codrici
LALucian Albulescu
Lucian Albulescu
IPIonela Daniela Popescu
Ionela Daniela Popescu
SMSimona Mihai
Simona Mihai
AEAna-Maria Enciu
Ana-Maria Enciu
MHMihail Eugen Hinescu
Mihail Eugen Hinescu
Caveolin-1 (CAV1) is the scaffold protein of caveolae, which are minute invaginations of the cell membrane that are involved in endocytosis, cell signaling, and endothelial-mediated inflammation. CAV1 has also been reported to have a dual role as either a tumor suppressor or tumor promoter, depending on the type of cancer. Inflammation is an important player in tumor progression, but the role of caveolin-1 in generating an inflammatory milieu remains poorly characterized. We used a caveolin-1-knockout (CAV1−/−) mouse model to assess the inflammatory status via the quantification of the pro- and anti-inflammatory cytokine levels, as well as the ability of circulating lymphocytes to respond to nonspecific stimuli by producing cytokines. Here, we report that the CAV1−/−mice were characterized by a low-grade systemic proinflammatory status, with a moderate increase in the IL-6, TNF-α, and IL-12p70 levels. CAV1−/−circulating lymphocytes were more prone to cytokine production upon nonspecific stimulation than the wild-type lymphocytes. These results show that CAV1 involvement in cell homeostasis is more complex than previously revealed, as it plays a role in the inflammatory process. These findings indicate that the CAV1−/−mouse model could prove to be a useful tool for inflammation-related studies.

1 January 2016 in Disease Markers
Verified
Journal Article
Open access
PDF file
SMSimona Mihai
Simona Mihai
ECElena Codrici
Elena Codrici
IPIonela Daniela Popescu
Ionela Daniela Popescu
AEAna-Maria Enciu
Ana-Maria Enciu
ERElena Rusu
Elena Rusu
CTCristiana Tanase
Cristiana Tanase
Chronic kidney disease, despite being a “silent epidemic” disease, represents one of the main causes of mortality in general population, along with cardiovascular disease, which is the leading cause of poor prognosis for these patients. The specific objective of our study was to characterize the relationship between the inflammatory status, the bone disorders markers, and kidney failure in chronic kidney disease patient stages 2–4, in order to design a novel biomarker panel that improves early disease diagnosis and therapeutic response, thus being further integrated into clinical applications. A panel of proteomic biomarkers, assessed by xMAP array, which includes mediators of inflammation (IL-6, TNF-α) and mineral and bone disorder biomarkers (OPG, OPN, OCN, FGF-23, and Fetuin-A), was found to be more relevant than a single biomarker to detect early CKD stages. The association between inflammatory cytokines and bone disorders markers, IL-6, TNF-α, OPN, OPG, and FGF-23, reflects the severity of vascular changes in CKD and predicts disease progression. Proteomic xMAP analyses shed light on a new approach to clinical evaluation for CKD staging and prognosis.

12 August 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
IPIonela D. Popescu
Ionela D. Popescu
ECElena Codrici
Elena Codrici
SMSimona Mihai
Simona Mihai
CLCristina-Mihaela Luntraru
Cristina-Mihaela Luntraru
MNMihaela Neagu
Mihaela Neagu
CTCristiana Tanase
Cristiana Tanase
Studies on the immunopharmacological activities of various plant species have provided evidence for the high therapeutic potential of different extracts. These represent a promising alternative to reduce the inflammatory processes and, thus, diseases related to inflammation. Numerous scientific studies strongly suggest that diet plays an essential role in inflammation, and that certain dietary factors can act as preventive or treatment methods to lower inflammation. In the present study, a novel lingonberry‑based dietary supplement was investigated for the ability to suppress the inflammatory response in activated monocytes/macrophages. Based on cell viability/proliferation and cytotoxicity tests, concentrations between 40 and 130 µg/ml of the extracts showed a high viability/proliferation effect and no cytotoxic activity in monocyte/macrophage cells. To further investigate the anti‑inflammatory potential of our novel lingonberry‑based dietary supplement, we studied the effect of the extract on the inflammatory response in lipopolysaccharide (LPS)‑stimulated macrophages. We found that the extract exhibited a strong anti‑inflammatory potential by inhibiting the expression of major inflammatory cytokines [interleukin (IL)‑6, IL‑8 and tumor necrosis factor (TNF)α] in activated monocyte/macrophage cells. The expression of IL‑6 and IL‑8 was subsequently validated by enzyme‑linked immunosorbent assay (ELISA). In conclusion, we demonstrated that our product exhibits no cytotoxicity and suppresses inflammation, and thus can be considered a natural important tool for inflammation control.